NGeneBio faces challenges after successful rights offering as fundraising shrinks by two-thirds

NGeneBio’s public offering following its rights issue drew demand 73.7 times the offering, marking a successful subscription. However, the actual amount raised fell to about one-third of the original plan because of the decline in the share price. The company has announced a new business in personalized precision diagnostics for GLP-1 obesity treatments, but it now faces the burden of funding research and development while repaying debt with reduced proceeds.

Fundraising sharply reduced despite successful public offering

NGeneBio disclosed the results of its public offering subscription through the electronic disclosure system on the 16th. For the planned issuance of 7.15 million shares, the cumulative number of subscribed shares, including subscriptions by existing shareholders and the public offering, reached 135,019,795, for a subscription rate of 1,888.39%. Existing shareholders subscribed for 5,392,147 shares, or 75.41% of the offered shares, while 1,757,853 unsubscribed forfeited shares were offered to the public. A total of 12,962,764 shares were subscribed for in the public offering, with 589 subscriptions and subscription deposits totaling 139.22009 billion won.

By allocation category, general subscribers applied for 12,591,979 shares, representing a subscription ratio of 119.4 to 1. High-risk, high-return investment trusts and similar vehicles recorded a ratio of 18.2 to 1, while venture investment trusts recorded 0.9 to 1. The refund and payment date is the 17th, and the new shares are scheduled to be listed on October 2.

Judging solely by the subscription ratio, the offering was successful, but the actual amount raised fell well short of the original target. NGeneBio issued a total of 7.15 million shares at 1,074 won per share, raising only about 7.7 billion won. That is approximately 34% of the 22.4 billion won planned when the offering was initially approved in April. In its securities registration statement, the company stated, “The decrease in actual proceeds resulting from the lower issue price may lead to a reduction or delay in planned uses of funds, including operating expenses and research and development.” As total proceeds declined, the proportion allocated to debt repayment surged from the original 22.8% to 52.1%, leaving substantially less funding for the new business and research and development.

Personalized diagnostics for obesity treatments and global expansion

Separately from its fundraising, NGeneBio has continued to pursue an aggressive business strategy. In August, the company announced plans to enter the market for personalized precision diagnostics for GLP-1 obesity treatments, for which demand is surging worldwide. Its plan is to develop a solution that predicts weight-loss efficacy and the risk of adverse effects through genetic analysis before treatment and monitors adverse reactions using blood-based testing during treatment. At the time of the new-business announcement, former CEO Min-sik Kim said, “We will actively expand the NGS and liquid biopsy technologies we have advanced in precision oncology into obesity and metabolic diseases.”

To support this effort, the company has signed memorandums of understanding with domestic medical institutions specializing in obesity, including Incheon Sejong Hospital, and is building a clinical cohort to track the genetic information, weight changes and adverse effects of Korean patients receiving GLP-1 treatment over the long term. Through this cohort, the company plans to identify new biomarkers reflecting the characteristics of Korean and Asian populations. These data could serve as a key asset for global pharmaceutical companies developing next-generation obesity treatments for the Asian market or selecting patients for clinical trials.

The company’s core NGS precision diagnostics business is also showing clear improvement. Consolidated revenue in the second quarter of 2026 was 12,452,070,000 won, up 574% from the same period a year earlier, while the operating loss narrowed by 55.8%. In particular, overseas precision diagnostics revenue more than doubled, providing quantitative evidence of the company’s global expansion. In July, it also signed a channel partner agreement with Illumina, the global leader in genomic analysis, establishing a foothold for expanding overseas sales channels.

Under new CEO, overcoming the lack of R&D funding is key

Immediately after completing the rights offering, NGeneBio replaced its management team on September 15 by appointing Kyung-nam Lee, who had overseen the company’s business strategy, as its new CEO. The appointment is interpreted as emphasizing stronger profitability and continuity in the existing business.

A business structure combining the two global themes of AI precision diagnostics and obesity treatments is sufficient to attract investor interest. However, with the reduction in the rights offering limiting research and development funding for the GLP-1 diagnostics business, the pace at which the company can increase its ability to generate cash internally through overseas sales is expected to be a key variable in its future valuation. The company has acknowledged that its financial position effectively limits other funding options, including borrowing from financial institutions and issuing bonds. As a result, the pace of performance improvement under the new CEO is emerging as a major focus for the market.